期刊文献+

血小板活化因子与大鼠肝脏病变的关系及银杏制剂的治疗作用

Relationship between platelet activating factor and liver damage in rats and the therapeutic effects of ginkgo preparation
下载PDF
导出
摘要 目的探讨血小板活化因子(PAF)与实验大鼠肝脏病变的关系及银杏制剂的治疗作用。方法将实验用Wistar大鼠60只,随机分成正常对照组(12只)、肝纤维化模型组(16只)、银杏制剂低剂量治疗组(16只)及银杏制剂高剂量治疗组(16只)4组。除正常对照组外,余3组应用CCl4皮下注射造模,2次/w,共12 w。正常对照组及模型组每日用生理盐水灌胃,而治疗组则每日用银杏制剂灌胃。12 w后,将全部大鼠处死,留取血清、肝组织,测定肝功能(ALT、ALB)、血清PAF及各种肝纤维化指标(HA、PⅢP、C-Ⅳ、LN),同时行组织病理学检查,并行胶原纤维增生程度半定量分析。结果模型组与正常对照组比较,除白蛋白降低外,血清PAF、ALT及各种肝纤维化指标均升高;各治疗组与模型组间比较,除白蛋白升高外,余各项指标均下降,同时肝脏炎症及肝纤维化程度减轻,上述指标差异均有统计学意义。结论 PAF与肝脏损伤及肝脏纤维化的发生有明显关系,PAF拮抗剂——银杏制剂有明显抑制和逆转肝纤维化的作用。 Objective To investigate the relationship of platelet activating factor(PAF)and liver damage in rats and the therapeutic effects of ginkgo preparation.Methods 60 Wistar rats were randomly divided into four groups:normal control group(n=12),liver fibrosis model group(model group,n=16),low dose gingko-treated group(n=16),high dose gingko-treated group(n=16).Except the normal control group,rats in other three groups were hypodermically injected with carbon tetrachloride(CCl4)twice a week.12 w later,the pathological examination showed that the model of hepatic fibrosis was successfully established.After that,the normal control group and the model group were intragastrically administered with normal saline every day and the two treated group were perfused with Ginkgo preparation at 50 or 100 mg/(kg·d),respectively.12 w later,all the rats were sacrificed and their liver tissues and sera were collected.Alanine aminotransferase(ALT)and albumin(ALB),serum PAF,hyaluronic acid(HA),pro-collagen peptide type Ⅲ(PⅢP),collagen type Ⅳ(C-Ⅳ)and laminin(LN)were measured.Meanwhile,pathological examination was performed for the semiquantitative analysis of the degree of liver fibrosis.Results Compared with the normal control group,PAF,ALT,PⅢP,C-Ⅳ,LN and HA increased significantly in the model group except that ALB reduced.Compared with the model group,all indexes in the two treated groups decreased significantly except that ALB increased,and the degree of liver inflammation and fibrosis mitigated significantly.These differences all had statistic significance.Conclusion PAF appears to be apparently associated with liver damage and liver fibrosis.Ginkgo preparation,a PAF antagonist,can obviously inhibit and reverse liver fibrosis.
出处 《西南国防医药》 CAS 2011年第3期246-249,共4页 Medical Journal of National Defending Forces in Southwest China
关键词 血小板活化因子 银杏制剂 肝纤维化 血小板活化因子拮抗剂 platelet activating factor ginkgo preparation platelet activating factor antagonist
  • 相关文献

参考文献12

  • 12006年~2010年全国乙型病毒性肝炎防治规划[J].中国实用乡村医生杂志,2006,13(8):1-4. 被引量:51
  • 2何云,袁凤仪,任渝江,袁红波,李凌,程忠良.银杏内酯对小鼠急性肝坏死的保护作用[J].中华传染病杂志,2001,19(6):368-370. 被引量:1
  • 3Zhang C,Zu J, Shi H, et al. The effect of Ginkgo biloba extract ( EGb 761 ) on hepatic sinusoidal endothelial cells and hepatic microcirculation in CC14 rats[J]. Am J Chin Med ,2004,32( 1 ) : 21 - 31.
  • 4何云,袁凤仪,王建宾,黄晓欣,袁红波,邵淑莲.Clinical Study on Treatment of Liver Fibrosis of Chronic Hepatitis B Patients with Ginkgo Leaf[J].Chinese Journal of Integrative Medicine,2002,8(2):90-94. 被引量:1
  • 5Nakamure T, Morita Y, Kuiyama M. Platelet activating factor in late asthmatic response [J]. Ant Allergy Appl Immunol, 1987, 82:57 - 62.
  • 6王泰龄,刘霞,周元平,何静雯,张晶,李宁章,段钟平,王宝恩.慢性肝炎炎症活动度及纤维化程度计分方案[J].中华肝脏病杂志,1998,6(4):195-197. 被引量:388
  • 7Yang Y, Harvey S A, Gandhi C R. Kupffer cells are a major source of increased platelet activating factor in the CCI4- inducedcirrhotic rat liver[J]. J Hepatol,2003,39(2) :200 -207.
  • 8Yang Y, Nemoto E M, Harvey S A, et al. Increased hepatic platelet activating factor(PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis[ J]. Gut ,2004,53(6) :877 - 883.
  • 9Lichtinghagen R, Bahr M J. Noninvasive diagnosis of fibrosis in chronic liver disease [ J ]. Expert Rev Mol Diagn, 2004,4 ( 5 ) : 715 - 726.
  • 10Saito H, Tada S, Nakamoto N, et al. Efficacy of non - invasive elastomctry on staging of hepatic fibrosis [ J ]. Hepatol Res, 2004,29(2) :97 - 103.

二级参考文献22

  • 1王泰龄,刘霞,高琳,赵静波,王宝恩.对慢性肝炎分类、分级分期的探讨[J].肝脏病杂志,1995,3(3):130-133. 被引量:22
  • 2程明亮,丁一生,罗永芳,田苗,吴君,罗天永,吴亚云,刘琴,杨京.汉丹必妥治疗慢性活动性肝炎肝纤维化的临床研究[J].中国中西医结合杂志,1996,16(7):431-432. 被引量:22
  • 3韩伟 成会忠 等.大鼠肝枯否细胞分离培养与免疫活性的研究[J].解剖学杂志,1998,11:71-72.
  • 4王宇明 丁健 等.内毒素/肿瘤坏死因子所致肝细胞损伤机制的体外研究[J].中华传染病杂志,1996,:14-15.
  • 5[1]Kleder G, Wiedr C, Heuer C, et al. Evidence for systemic release of platelet activating factor in liver disease. J Hepatol, 1996; 23(1)∶127-130.
  • 6[2]ZENG NX, WANG JJ. Platelet activating factor determination in patients with liver cirrhosis and its relationship with endotoxinemia. Chin Med J 1992;72(2)∶141-143.
  • 7[3]HE Y, GU CH, WANG YM, et al. Significance of changes of platelet activating factor level in patients with chronic severe hepatitis. Chin J Infect Dis 2000;18(1)∶49-50.
  • 8[4]CHEN ZN. Progression of study on anti-platelet activating factors in medicinal plants. Chin J Chinese Materia Medica 1993;18(6)∶323-325.
  • 9[5]Branch of Infectious, Parasitic Diseases and Hepatopathy of Chinese Association of Medicine. Program of Prevention and Treatment of Viral Hepatitis. Chin J Hepato 2000; 8(6)∶324-329.
  • 10[6]Nakamura T, Morita Y, Kuriyama M, et al. Platelet activating factor in late asthmatic response. In Arch Allergy Appl Immunol 1987;82(1)∶57-62.

共引文献458

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部